Skip to main content

Table 1 Patient baseline characteristics ( n  = 37)

From: Phase I study of azacitidine and oxaliplatin in patients with advanced cancers that have relapsed or are refractory to any platinum therapy

Clinical characteristic

Number of patients (%)

Sex

 

 Men

18 (49)

 Women

19 (51)

Age (years)

 

 Median (range)

58 (31 to 79)

Race

 

 White

26 (70)

 African-American

8 (22)

 Asian

3 (8)

No. of prior therapies

 

 Median (range)

4 (1 to 10)

Time from diagnosis to the first cycle (months)

 

 Median (range)

35.5 (4 to 121)

ECOG

 

 0

4 (11)

 1

33 (89)

RMH score

 

 0 to 1

28 (76)

 2 to 3

9 (24)

Tumor types

 

 CRC

23 (62)

 Gynecological

4 (11)

 Lung

4 (11)

 Head and neck

3 (8)

 Othera

3 (8)

  1. ECOG, Eastern Cooperative Oncology Group; RMH, Royal Mandersen Hospital; CRC, colorectal cancer. aCholangiocarcinoma (n = 1), breast cancer (n = 1), and esophageal cancer (n = 1).